PCM
RPRX icon

Portolan Capital Management’s Royalty Pharma RPRX Stock Holding History

Portolan Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-352,257
Closed -$11M – 137
2025
Q1 		$11M Buy
352,257
+8,072
+2% +$256K 0.83% 43
2024
Q4 		$8.78M Buy
344,185
+173,721
+102% +$4.61M 0.59% 62
2024
Q3 		$4.82M Buy
+170,464
New +$4.72M 0.35% 88
2024
Q2 		– Sell
-288,378
Closed -$8.76M – 131
2024
Q1 		$8.76M Buy
288,378
+138,551
+92% +$4.08M 0.67% 54
2023
Q4 		$4.21M Buy
149,827
+71,475
+91% +$1.96M 0.37% 83
2023
Q3 		$2.13M Sell
78,352
-60,139
-43% -$1.79M 0.2% 107
2023
Q2 		$4.26M Sell
138,491
-73,962
-35% -$2.51M 0.38% 77
2023
Q1 		$7.65M Buy
+212,453
New +$7.88M 0.73% 47

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Portolan Capital Management's RPRX Position: Q2 2025 in Review

Portolan Capital Management sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 352,257 shares — an estimated $11M sold.

Portolan Capital Management first reported a position in RPRX in Q1 2023 and held it in 8 quarters. The position peaked at $11M in Q1 2025. 454 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Portolan Capital Management reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Portolan Capital Management sold 352,257 Royalty Pharma shares in Q2 2025, an estimated $11M.
  • Portolan Capital Management first reported a position in Royalty Pharma in Q1 2023 and held it in 8 quarters.
  • Portolan Capital Management's Royalty Pharma position peaked at $11M in Q1 2025.
  • 454 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Portolan Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.